1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Tien Liang Biotech Co., Ltd.

Tien Liang Biotech Co., Ltd.

TTPEX:4127
37.95
TWD
+0.40
(+1.07%)
1.51EPS
45.19P/E
3.13BMarket Cap
Tien Liang Biotech Co., Ltd.
TPEX:4127
(Taipei Exchange)

Recent

price

37.95

P/E

ratio

45.19

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
16.13
18.58
19.34
20.07
18.44
18.37
16.51
11.26
11.66
9.52
9.42
12.49
11.55
10.05
8.42
11.18
14.24
Revenue per Share
-0.56
-0.06
0.81
1.07
1.34
1.07
-1.17
-4.45
-2.07
-1.02
-1.13
1.02
1.3
0.39
0.26
-0.22
1.51
Basic EPS, GAAP
1.66
-0.36
1.86
2.41
0.81
1.33
-1.28
-2.5
-0.56
-0.95
-0.27
0.97
0.46
1.41
0.97
-0.09
0.38
Free Cash Flow per Basic Share
0.2
- -
- -
0.2
1
0.7
0.3
- -
- -
- -
- -
- -
- -
- -
0.5
- -
- -
Dividend per Share
15.78
15.73
16.52
17.48
17.82
18.17
16.72
12.16
10.18
9.16
8.03
9.05
10.38
10.77
10.44
10.36
11.35
Book Value per Share
10.76
10.62
11.61
12.57
12.9
13.25
12.1
11.4
10.15
9.13
8
9.03
10.38
10.76
10.43
10.35
11.34
Tangible Book Value per Share
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
Basic Weighted Avg Shares
738
850
885
918
844
841
756
515
534
436
431
571
529
460
385
512
651
Sales/Revenue/Turnover
-1.87
1.72
7.6
8.24
9.87
8.72
-4.27
-37.92
-12.25
-9.95
-11.76
7.52
11.03
4.1
0.15
-3.15
0.87
Operating Margin (%)
26
29
30
30
32
36
40
37
30
18
15
12
11
11
9
10
11
Depreciation Expense
-26
-3
37
49
61
49
-53
-203
-94
-47
-52
47
59
18
12
-10
69
Net Income, GAAP
- -
- -
25.81
23.11
19.23
22.67
- -
- -
- -
- -
- -
4.46
- -
3.71
10.7
- -
0.27
Effective Tax Rate (%)
-3.47
-0.31
4.18
5.34
7.29
5.84
-7.06
-39.48
-17.7
-10.73
-11.98
8.16
11.25
3.85
3.04
-2
10.62
Profit Margin (%)
54
49
95
181
101
-19
7
122
122
77
11
71
141
164
-161
-424
-388
Working Capital
302
307
289
343
306
177
242
67
50
33
2
1
1
- -
- -
- -
- -
LT Debt
722
720
756
800
816
832
765
556
466
419
367
414
475
493
478
474
519
Total Equity
- -
- -
3.25
4.31
5.03
4.28
- -
- -
- -
- -
- -
7.31
- -
3.37
-0.01
- -
0.54
Return on Invested Capital (%)
- -
- -
3.54
4.4
5.3
4.35
- -
- -
- -
- -
- -
8.62
- -
3.38
2.06
- -
7.82
Return on Capital (%)
-3.46
-0.37
5.01
6.3
7.61
5.96
-6.68
-30.8
-18.49
-10.57
-13.13
11.93
13.38
3.66
2.41
-2.15
14.25
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
599
599
599
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
46
46
46
Market Capitalization
1,419
1,647
3,125

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
285
313
316
Cash, Cash Equivalents & STI
152
171
197
Accounts Receivable, Net
43
63
47
Inventories
67
63
55
Total Current Liabilities
709
716
704
Payables & Accruals
- -
- -
- -
ST Debt
599
599
599
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-4.66%
5.48%
-0.81%
Free Cash Flow
-62.69%
-89.45%
-109.2%
Net Income, GAAP
-47.52%
-90.9%
-187.65%
Sales/Revenue/Turnover
-2.91%
5.73%
32.86%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
118
83
97
87
385
2025
117
127
136
132
512
2026
198
185
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.17
-0.08
0.07
0.1
0.26
2025
0.39
-1.06
0.51
-0.06
-0.22
2026
0.75
0.31
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.5
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Tien Liang BioTech Co., Ltd. manufactures and sells pharmaceutical products, including traditional Chinese medicines and Western medicines, in Taiwan and internationally. The company offers Chinese medicine products such as pills addressing liver and kidney deficiency, low back pain, sore feet, dizziness, thirst, dry tongue, sore throat, heel pain, rheumatism, joint pain, traveling pain, wind-cold-dampness, gout, neuralgia, enuresis, hemorrhoids, constipation, athlete's foot, fall injuries, cold, bronchitis, cough, and phlegm; Western medicine products including ointments, hair removal creams, tablets, capsules, soreness sprays, pain patches, and pain relief gels; healthcare products; and other items for body relaxation, post-exercise comfort relief, tooth care, and soaps. Founded in 1960 and headquartered in New Taipei City, Taiwan, Tien Liang BioTech operates primarily in the pharmaceuticals sector, focusing on domestic distribution with international sales, and maintains ongoing import, wholesale, and retail activities for health food and active pharmaceutical ingredients. In recent developments, the company reported Q2 2025 revenue of NT$127.3 million alongside a net loss of NT$48.6 million, reflecting continued financial operations amid a stable business structure with no major acquisitions, partnerships, or strategic shifts announced in the past 1-2 years.